Literature DB >> 29122528

Safety of open ventral hernia repair in high-risk patients with metabolic syndrome: a multi-institutional analysis of 39,118 cases.

Dmitry Zavlin1, Kevin T Jubbal2, Jeffrey L Van Eps3, Barbara L Bass3, Warren A Ellsworth4, Anthony Echo4, Jeffrey D Friedman4, Brian J Dunkin3.   

Abstract

BACKGROUND: Metabolic syndrome (MetS) entails the simultaneous presence of a constellation of dangerous risk factors including obesity, diabetes, hypertension, and dyslipidemia. The prevalence of MetS in Western society continues to rise and implies an elevated risk for surgical complications and/or poor surgical outcomes within the affected population.
OBJECTIVE: To assess the risks and outcomes of multi-morbid patients with MetS undergoing open ventral hernia repair.
SETTING: Multi-institutional case-control study in the United States.
METHODS: The American College of Surgeons National Surgical Quality Improvement Program database was sampled for patients undergoing initial open ventral hernia repair from 2012 through 2014 and then stratified into 2 cohorts based on the presence or absence of MetS. Statistical analyses were performed to evaluate preoperative co-morbidities, intraoperative details, and postoperative morbidity and mortality to identify risk factors for adverse outcomes.
RESULTS: Mean age (61.0 versus 56.0 yr, P<.001), body mass index (39.2 versus 31.1, P<.001), and prevalence of co-morbidities of multiple organ systems were significantly higher (P<.001) in the MetS cohort compared to control. Patients with MetS received higher American Society of Anesthesiologists classifications (81.0% versus 43.1% class 3 or higher, P<.001), were more likely to require operation as emergency cases (11.4% versus 7.2%, P<.001), required longer operative times (103 versus 87 min, P<.001), had longer hospitalizations (3.5 versus 2.4 d, P<.001), and had more contaminated wounds (15.9% versus 12.0% class 2 or higher, P<.001). Overall, they had more medical (7.5% versus 4.2%, P<.001), and surgical complications (9.7% versus 5.4%, P<.001), experienced more readmissions (8.3% versus 5.7%, P<.001) and reoperations (3.4% versus 2.5%, P<.001), and were at higher risk for eventual death (.8% versus .5%, P=.008).
CONCLUSIONS: The presence of MetS is related to a multitude of unfavorable outcomes and increased mortality after open ventral hernia repair compared with a non-MetS control group. MetS is a useful marker for high operative risk in a population that is generally prone to obesity and its associated diseases.
Copyright © 2018 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metabolic syndrome; Obesity; Outcomes; Risk factors; Secondary procedures; Ventral hernia repair

Mesh:

Year:  2017        PMID: 29122528     DOI: 10.1016/j.soard.2017.09.521

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  4 in total

1.  Frailty predicts morbidity, complications, and mortality in patients undergoing complex abdominal wall reconstruction.

Authors:  W J Joseph; N G Cuccolo; M E Baron; I Chow; E H Beers
Journal:  Hernia       Date:  2019-09-18       Impact factor: 4.739

Review 2.  Excess Body Weight and Abdominal Hernia.

Authors:  Ulrich A Dietz; Omar Yusef Kudsi; Fahri Gokcal; Naseem Bou-Ayash; Urs Pfefferkorn; Gottfried Rudofsky; Johannes Baur; Armin Wiegering
Journal:  Visc Med       Date:  2021-04-28

3.  Metabolic Syndrome (MetS), Systemic Inflammatory Response Syndrome (SIRS), and Frailty: Is There any Room for Good Outcome in the Elderly Undergoing Emergency Surgery?

Authors:  Pietro Fransvea; Gianluca Costa; Luca Lepre; Gabriella Teresa Capolupo; Filippo Carannante; Caterina Puccioni; Alessandro Costa; Antonio La Greca; Francesco Giovinazzo; Gabriele Sganga
Journal:  Front Surg       Date:  2022-06-15

4.  Management of ventral hernia in patients with BMI > 30 Kg/m2: outcomes based on an institutional algorithm.

Authors:  S J Baig; P Priya
Journal:  Hernia       Date:  2020-10-12       Impact factor: 4.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.